The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of TGR-1202, a novel once-daily PI3Kδ inhibitor, in patients with relapsed or refractory hematologic malignancies.
Howard A. Burris
Research Funding - TG Therapeutics
Manish R. Patel
Research Funding - TG Therapeutics
Mark C. Lanasa
Research Funding - TG Therapeutics
Danielle Brander
Research Funding - TG Therapeutics
Owen A. O'Connor
Research Funding - TG Therapeutics
Changchun Deng
Research Funding - TG Therapeutics
Martin Gutierrez
Research Funding - TG Therapeutics
Suzanne Fields Jones
No relevant relationships to disclose
John G. Kuhn
Consultant or Advisory Role - TG Therapeutics
Hari P. Miskin
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Peter Sportelli
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Swaroop Vakkalanka
Employment or Leadership Position - Rhizen Pharmaceuticals
Stock Ownership - Rhizen Pharmaceuticals
Ian Flinn
Research Funding - TG Therapeutics